InsidersTradesSigma
Cumberland Pharmaceuticals INC Stock: price and management transactions · United States · SEC (Form 4)
Follow the Cumberland Pharmaceuticals INC share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cumberland Pharmaceuticals INC has logged 209 public disclosures. Market capitalisation: €90.5m. The latest transaction was disclosed on 20 March 2026 (Attribution). Among the most active insiders: Krogulski Kenneth. All data is accessible without an account.
209
Insider Decl.
0
Thresholds
€22,083
109 ops.
Buy Volume
·
0 ops.
Sell Volume
60Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,479 of 26,180 companies
35.1
score / 100
Value33
Quality38
FCF yld5.2%
Earn yld-3.1%
EV/EBITDA33.9x
ROE-30%
Gross mgn85%
Net mgn-6.4%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 March 2026
Declarations209 total
1,800 shares@ US$2.8017.8% of flowCommon StockSEC:0001632384-26-000002:0
1,800 shares@ US$2.8026.5% of flowCommon StockSEC:0001087294-26-000040:0
1,800 shares@ US$2.8018.3% of flowCommon StockSEC:0001087294-26-000039:0
1,800 shares@ US$2.808.4% of flowCommon StockSEC:0001087294-26-000037:0
1,800 shares@ US$2.8018.9% of flowCommon StockSEC:0001087294-26-000036:0
5,845 shares@ US$3.065.3% of flowCommon StockSEC:0001628280-26-019514:0
4 shares@ US$3.54Common StockSEC:0001684087-25-000004:0
6 shares@ US$3.440.1% of flowCommon StockSEC:0001628280-25-041989:0
Ideal exit: 28 Apr 2026 (T+270)
13 shares@ US$3.440.2% of flowCommon StockSEC:0001628280-25-041987:0
Ideal exit: 28 Apr 2026 (T+270)
13 shares@ US$3.440.0% of flowCommon StockSEC:0001628280-25-041985:0
Ideal exit: 28 Apr 2026 (T+270)
68 shares@ US$3.440.4% of flowCommon StockSEC:0001628280-25-041983:0
Ideal exit: 28 Apr 2026 (T+270)
8 shares@ US$3.560.1% of flowCommon StockSEC:0001628280-25-039411:0
Ideal exit: 28 Mar 2026 (T+270)
16 shares@ US$3.560.2% of flowCommon StockSEC:0001628280-25-039404:0
Ideal exit: 28 Mar 2026 (T+270)
16 shares@ US$3.560.0% of flowCommon StockSEC:0001628280-25-039400:0
Ideal exit: 28 Mar 2026 (T+270)
80 shares@ US$3.560.5% of flowCommon StockSEC:0001628280-25-039397:0
Ideal exit: 28 Mar 2026 (T+270)
4 shares@ US$5.200.1% of flowCommon StockSEC:0001628280-25-034820:0
Ideal exit: 27 Feb 2026 (T+270)
8 shares@ US$5.200.0% of flowCommon StockSEC:0001628280-25-034818:0
Ideal exit: 27 Feb 2026 (T+270)
8 shares@ US$5.200.2% of flowCommon StockSEC:0001628280-25-034816:0
Ideal exit: 27 Feb 2026 (T+270)
45 shares@ US$5.200.4% of flowCommon StockSEC:0001628280-25-034814:0
Ideal exit: 27 Feb 2026 (T+270)
45 shares@ US$4.860.4% of flowCommon StockSEC:0001628280-25-029856:0
Ideal exit: 26 Jan 2026 (T+270)
8 shares@ US$4.860.2% of flowCommon StockSEC:0001628280-25-029854:0
Ideal exit: 26 Jan 2026 (T+270)
4 shares@ US$4.860.1% of flowCommon StockSEC:0001628280-25-029852:0
Ideal exit: 26 Jan 2026 (T+270)
8 shares@ US$4.860.0% of flowCommon StockSEC:0001628280-25-029849:0
Ideal exit: 26 Jan 2026 (T+270)
8 shares@ US$4.240.1% of flowCommon StockSEC:0001628280-25-024353:0
Ideal exit: 27 Dec 2025 (T+270)
4 shares@ US$4.240.1% of flowCommon StockSEC:0001628280-25-024355:0
Ideal exit: 27 Dec 2025 (T+270)
25 of 209 declarations
About Cumberland Pharmaceuticals INC
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company listed on the Nasdaq under the ticker CPIX, in the United States. Headquartered in Nashville, Tennessee, the company develops, acquires, and commercializes branded prescription medicines, with a strategy focused on therapeutic niches where unmet medical needs remain significant. For French-speaking investors in France, Belgium, or Switzerland, Cumberland fits the profile of a U.S. small/mid-cap healthcare company with a mix of commercial execution and targeted development, rather than a broad-platform biotech. The company was founded in the early 2000s and has built its business by acquiring rights to established brands, reviving growth in those assets, and maintaining a more selective early-stage development pipeline through its development affiliate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1087294/000108729426000020/cpix-20251231.htm?utm_source=openai)) Cumberland’s core business is built around FDA-approved branded products used primarily in hospital settings, specialty care, and selected niche indications. The company also maintains development assets through Cumberland Emerging Technologies to help advance early-stage candidates. Products and assets referenced in recent filings and releases include Vibativ, Sancuso, and the ifetroban program. In competitive terms, Cumberland is positioned as an agile specialty pharma operator that seeks to monetize existing assets while creating value in indications with meaningful unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001087294/000108729426000020/cpix-20251231.htm?utm_source=openai)) Geographically, the group remains a U.S.-based business with headquarters in the United States, but it has an increasingly international footprint as it expands certain products and secures approvals outside its domestic market. Recent disclosures highlight new international approvals and continued portfolio progress. During 2025, Cumberland reported revenue growth and stronger operational execution; in 2026, it announced a major strategic transaction with an affiliate of Apotex to integrate its commercial business in exchange for $100 million, while sharpening its focus on orphan-drug candidates and higher-upside development programs. This is an important strategic inflection point, as it reduces the company’s dependence on mature commercial brands and increases capital available for the next phase of growth. ([investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai)) Overall, Cumberland Pharmaceuticals Inc. is a U.S.-listed specialty pharma company on the Nasdaq that combines marketed products, branded-asset management, and focused pipeline development. For international equity investors, the key appeal lies in its specialty pharmaceutical model, disciplined portfolio approach, and recent regulatory and strategic catalysts. The latest company communications point to improving operating momentum through 2025, followed by a significant repositioning in early 2026 around the company’s most promising assets. ([investor.cumberlandpharma.com](https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025?utm_source=openai))
